SPEC - Handbook of Clinical Neurology, Volume 144, Huntington Disease, 12-Month Access, eBook

Section 1 Basic Science 1. Genetics of Huntington disease 2. Mechanisms underlying neurodegeneration in Huntington disease: Applications to novel disease-modifying therapies

Section 2 Clinical Aspects 3. Epidemiology of Huntington disease 4. Statistical modelling of Huntington disease onset 5. The diagnosis and natural history of Huntington disease 6. Preclinical cognitive and behavioral changes in Huntington disease 7. Preclinical motor manifestations of Huntington disease 8. The highly anxious individual presenting for Huntington disease predictive genetic testing: the psychiatrist's role in assessment and counseling 9. Reproductive options for Huntington disease families 10. Genetic testing for Huntington disease

Section 3 Treatment of Huntington Disease 11. Medical treatment of behavioral manifestations of Huntington disease 12. Medical management of motor manifestations of Huntington disease 13. The role of rehabilitation therapy in Huntington disease 14. Contemporary health care for Huntington disease 15. The impact of Huntington disease on young people 16. Making a measurable difference in advanced Huntington disease care

Section 4 Experimental Therapeutics 17. New symptomatic therapies for Huntington disease 18. Motor outcome measures in Huntington disease clinical trials 19. Cognitive outcome measures in Huntington disease clinical drug trials

Section 5 Biomarkers 20. Structural imaging in premanifest and manifest Huntington disease 21. Functional imaging in Huntington disease

Dr. Feigin is a Professor of Neurology and Molecular Medicine at the Hofstra Northwell School of Medicine. He directs the Huntington's Disease Center at North Shore University Hospital and the Laboratory of Experimental Therapeutics for Movement Disorders at The Feinstein Institute for Medical Research of the Northwell Health System in Manhasset, NY. Dr. Feigin has been involved in Huntington's disease (HD) clinical research for more than 20 years; he participated in the Venezuela HD project for 10 years beginning in 1993. He has been a site principal investigator on more than 30 National Institute of Health and industry sponsored clinical trials of new treatments for HD and Parkinson's disease (PD), and he has been a principal investigator on several multicenter clinical trials for HD and PD. His independent research focuses on using state-of-the-art imaging methods to elucidate the mechanisms underlying current therapies for movement disorders. This work has led to the use of imaging as a biomarker in clinical trials of novel therapies for HD and PD. In addition, Dr. Feigin is interested in utilizing imaging as a biomarker for HD in the premanifest phase of illness. Dr. Feigin has served in many leadership roles for national and international academic consortiums studying HD including the Huntington Study Group. In addition, he remains a committed and busy clinician caring for patients and families with HD and other Movement Disorders. Karen E. Anderson, MD is Director of the Huntington Disease Care, Education and Research Center (HDCERC), a joint endeavor of Georgetown University Medical Center (GUMC) and MedStar Georgetown University Hospital.Dr. Anderson is a neuropsychiatrist with dual appointments in the departments of psychiatry and neurology; she leads a team of neurologists, psychiatrists, neuropsychologists, genetic counselors, social workers and other specialists who make up the Huntington Disease Center.



Dr. Anderson's work combines